Thermo Fisher Scientific reported Q2 2025 revenue of $10.86 billion, beating analyst estimates, driven by a 6% rise in life sciences solutions. Adjusted earnings per share were $5.36, surpassing consensus. Reflecting strong financial performance and effective cost-cutting actions, the company raised its full-year 2025 revenue guidance to $43.6-$44.2 billion and adjusted EPS to $22.22-$22.84. The firm anticipates continued organic revenue growth despite macroeconomic headwinds, including easing US-China tariff tensions, and plans CFO transition by March 2026. Investors responded positively with an 11% stock increase.